AZD6280 Multiple Ascending Dose Study
Completed · Phase 1
Conditions studied: Healthy Volunteer
In brief
This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD6280 after single and repeated ascending doses.
Key facts
- Study ID
- NCT00681317
- Run by
- AstraZeneca
- People needed
- 48
- Starts
- 2008-03-01
- Expected to finish
- 2008-07-01
- Last updated by the study team
- 2010-12-09
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Female subjects must be of non-child bearing potential.
You may not qualify if…
- Clinically significant illness within 2 weeks before the study start.
- Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
- Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
- Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
Where it is running
- Research Site — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.